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Background: Mutations in either Aβ Precursor protein (APP) or genes that regulate APP processing, such as BRI2/
ITM2B and PSEN1/PSEN2, cause familial dementias. Although dementias due to APP/PSEN1/PSEN2 mutations are
classified as familial Alzheimer disease (FAD) and those due to mutations in BRI2/ITM2B as British and Danish
dementias (FBD, FDD), data suggest that these diseases have a common pathogenesis involving toxic APP
metabolites. It was previously shown that FAD mutations in APP and PSENs promote activation of caspases leading
to the hypothesis that aberrant caspase activation could participate in AD pathogenesis.
Results: Here, we tested whether a similar mechanism applies to the Danish BRI2/ITM2B mutation. We have
generated a genetically congruous mouse model of FDD, called FDDKI, which presents memory and synaptic
plasticity deficits. We found that caspase-9 is activated in hippocampal synaptic fractions of FDDKI mice and
inhibition of caspase-9 activity rescues both synaptic plasticity and memory deficits.
Conclusion: These data directly implicate caspase-9 in the pathogenesis of Danish dementia and suggest that
reducing caspase-9 activity is a valid therapeutic approach to treating human dementias.Background
The prevailing pathogenic model for dementias caused
by mutations in APP and genes that regulate APP pro-
cessing (PSEN1, PSEN2 and BRI2/ITM2b) posits that
amyloid peptides trigger dementia. In AD, the amyloid
peptide is Aβ that derives from APP processing. β-
cleavage of APP, which is inhibited by BRI2, yields
amino-terminal-soluble APPβ (sAPPβ) and β-carboxyl-
terminal fragments (β-CTF). Processing of β-CTF by the
γ-secretase complex, of which PSEN1 and PSEN2 con-
stitute the catalytic components, releases Aβ. In FDD
and FBD the amyloidogenic peptides, called ADan and
ABri respectively, are generated from the mutant BRI2
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reproduction in any medium, provided the orTo model FDD we generated FDDKI mice that, like
FDD patients [1], carry a wild type Bri2/Itm2b allele and
a Danish mutated allele [2]. FDDKI mice develop pro-
gressive synaptic and memory deficits due to loss of
BRI2 protein [3]. Owing to the loss of BRI2, processing
of APP is increased in FDD [4,5], and sAPPβ/β-CTF, but
not Aβ, trigger memory and synaptic deficits of FDDKI
mice [4,6,7]. These observations are consistent with the
recent findings that β-processing of APP, but not Aβ,
triggers pathological modifications associated with AD
in human neurons derived from both familial and spor-
adic AD cases [8] and that a mutation in APP that
reduces the BACE1 cleavage of APP protect elderly indi-
vidual from sporadic AD and normal memory loss asso-
ciated with ageing [9]. These similarities suggest that
FDD shares common pathogenic mechanisms with FAD,
involving synaptic-toxic APP metabolites distinct from
Aβ.
We and others have shown that FAD mutations in
APP and PSENs could promote activation of caspasesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Z-VAD-fmk and Z-LEHD-fmk rescue the synaptic
deficits of FDDKI mice. Vehicle-treated slices from FDDKI mice
exhibited a reduction in LTP compared to slices from vehicle-treated
WT littermates [WT/vehicle vs. FDD/vehicle: F(1,12) = 27.008, P <
0.0001]. Perfusion with either 10 μM Z-VAD-fmk or 2 μM Z-LEHD-fmk
reverses the LTP impairment of FDDKI slices [WT/vehicle vs. FDD/Z-
VAD-fmk: F(1,12) = 0.191, P = 0.671. FDD/vehicle vs. FDD/Z-VAD-fmk:
F(1,12) = 14.300, P = 0.003. WT/vehicle vs. FDD/Z-LEHD-fmk: F(1,12) =
34.592, P < 0.0001. FDD/vehicle vs. FDD/Z-LEHD-fmk: F(1,12) = 34.592,
P < 0.0001] but did not alter normal LTP responses in WT mice [WT/
vehicle vs. WT/Z-VAD-fmk: F(1,12) = 0.032, P = 0.861. WT/vehicle vs.
WT/ Z-LEHD-fmk: F(1,12) = 0.016, P = 0.900]. Differently, treating slices
with 2 μM Z-DEVD-fmk did not overall rescue synaptic plasticity
deficits of FDDKI mice [WT/vehicle vs. FDD/Z-DEVD-fmk: F(1,12) =
0.191, P = 0.671. FDD/vehicle vs. FDD/Z-DEVD-fmk: F(1,10) = 4.272;
P = 0.063], albeit it delayed the initiation of such deficits. In fact Z-
DEVD-fmk rescued the LTP deficit during the initial 45 min of LTP
[FDD/vehicle vs. FDD/Z-DEVD-fmk: F(1,10) = 8.93, P = 0.012], but not
the deficit occurring during the last 45 min of LTP [FDD/vehicle vs.
FDD/Z-DEVD-fmk: F(1,10) = 1.23, P = 0.29]. Of note, Z-DEVD-fmk did
not alter LTP in WT mice [WT/vehicle vs. WT/Z-DEVD-fmk: F F(1,10) =
1.968, P = 0.191]. CA1-LTP was induced through a θ burst stimulation
of the Shaffer collateral pathway.
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caspases could play a pathogenic role in AD. In the en-
suing years, a vast literature has linked Aβ to caspase ac-
tivation, especially caspase-3, but a functional link has
not been proven [15]. However, other reports have indi-
cated that APP metabolites derived either from sAPPβ
or the intracellular portion of β-CTF, and distinct from
Aβ, also can promote activation of caspases [16-19].
Most caspases are mainly involved in the orchestration
of the controlled demise of a cell after an apoptotic sig-
nal. These caspases are divided into those that initiate
the apoptotic cascade (caspase-2, -8, -9 and −10, “initi-
ator” caspases) and those that that execute apoptosis
(caspase-3, -6, and −7, “effector” caspases). Initiator cas-
pases are usually activated by dimerization, while effector
caspases are activated by cleavage by initiator caspases
[20]. Several recent observations show that apoptotic cas-
pases also regulate other pathways including synaptic plas-
ticity [21]. Based on these observations we tested whether
caspases take part in the pathogenesis of memory loss and
synaptic plasticity deficits of FDDKI mice.
Results
The caspase inhibitors Z-VAD-fmk and Z-LEHD-fmk, but
not Z-DEVD-fmk, rescue the synaptic plasticity deficits of
FDDKI mice
In 1928 Ramon y Cajal predicted that weakening of
synapses leads to dementia. Long-term potentiation
(LTP) is a synaptic plasticity phenomenon that underlies
the strengthening of synaptic functions during memory
acquisition. Consistent with Ramon y Cajal’s prediction,
LTP is defective in the hippocampal Schaffer collateral
pathway of FDDKI mice. However, basal synaptic trans-
mission and paired-pulse facilitation are normal in
FDDKI mice, suggesting that no changes in Ca
2+
mobilization or alterations in the probability of neuro-
transmitter release are driven by the Danish mutation
[3]. To examine the role of caspases in synaptic plasti-
city, we analyzed the effect of the cell-permeable, irre-
versible pan-caspase inhibitor Z-VAD-fmk on LTP.
Hippocampal slices were perfused either with Z-VAD-
fmk (at 10 μM concentration) or vehicle for 60 min be-
fore inducing LTP. Z-VAD-fmk reversed the LTP deficit
of Danish samples and did not alter LTP in wild-type
mice (Figure 1).
Most caspases are expressed in the hippocampus. To
start dissecting which caspase(s) play(s) a role in LTP
deficits in FDDKI mice, we analyzed the effect of Z-
LEHD-fmk and Z-DEVD-fmk, which have partially over-
lapping inhibitory patterns of caspases inhibition. As
shown in Figure 1, Z-LEHD-fmk behaved similarly to Z-
VAD-fmk (i.e. it fully rescued the LTP deficit of FDDKI
mice, without imposing on normal synaptic plasticity).
In contrast, LTP Z-DEVD-fmk delayed, but did notrescue, the insurgence of LTP deficits in FDDKI mice
(Figure 1). The evidence indicates that some, but per-
haps not any, caspases are involved in the pathogenesis
of LTP deficits of FDDKI mice.
The caspase inhibitor Z-LEHD-fmk, but not Z-DEVD-fmk,
rescues the object recognition deficits of FDDKI mice
We reasoned that if caspases have a causative role in de-
mentia, then inhibiting caspase activity should in
addition rescue memory deficits of FDDKI mice. To test
for this, we analyzed the effect of Z-LEHD-fmk and Z-
DEVD-fmk on the memory deficits of FDDKI mice in a
longitudinal study. Memory was analyzed using novel
object recognition (NOR), a non-aversive memory test
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The first NOR study showed that during training, FDDKI
and WT mice spent the same amount of time exploring
two identical objects (Figure 2A, left panel), showing no
discrimination between these two identical objects
(Figure 2A, right panel). The following day, one of the two
old objects was replaced with a new one to test the
mouse’s memory. WT mice preferentially explored the
novel object; conversely FDDKI mice spent the same
amount of time exploring the two objects as if they were
both novel to them, showing that they had no memory of
the objects from the previous day (Figure 2B, the left panel
shows the time spent exploring each object, while the right
panel show the discriminatory ratio). After this first test,
the mice were rested for one day before re-testing. In this
second experiment, the mice were injected in the lateral
ventricle with Z-LEHD-fmk 1 h before the training/testing
trials. Treated FDDKI mice spent significantly more time
exploring the novel object, just as treated controls did
(Figure 2B). Following 2 days of rest, a new NOR test
performed without treatments showed that FDDKI mice
had relapsed into amnesia (Figure 2B), demonstrating
that the therapeutic effect of Z-LEHD-fmk is short-lived.
One day later, mice were injected 1 h before the training/
testing with Z-DEVD-fmk. Z-DEVD-fmk neither improved
memory of FDDKI mice nor altered performance of WT
animals (Figure 2B). Thus, Z-LEHD-fmk (which fully cor-
rected the synaptic deficit of FDDKI mice) rescued, albeit
temporarily, the memory deficit of FDDKI mice. In con-
trast, Z-DEVD-fmk (which, as show in Figure 1, was ineffi-
cient in normalizing LTP in FDDKI mice) did not.
Although Z-LEHD-fmk and Z-DEVD-fmk are commonly
referred to as specific caspase-9 and caspase3/7 inhibi-
tors, respectively, these compounds show overlapping se-
lectivity [22]. Therefore from these experiments it is
difficult to pinpoint the caspase(s) involved in these
pathogenic processes. However, altogether these data
suggest that one or more caspases mediate synaptic/
memory deficits of FDDKI mice.
The initiator caspase-9 is active in FDDKI mice hippocampal
synaptic fractions
Based on the evidence that caspases are pathogenic in
FDDKI mice, we sought biochemical evidence of caspase
activation and/or activity. Because FDDKI mice have def-
icits in hippocampal-dependent memory and synaptic
activity, which are associated with learning and memory,
we tested whether we could detect signs of caspase acti-
vation in hippocampal synaptic preparations of
12 month-old mice. As discussed above, caspases are
synthesized as zymogens (FL-caspase). Effector caspases
are cleaved by initiator caspases (cl.-caspase) and this
cleavage leads to activation of effector caspases. To allow
unequivocal identification of active caspase we used anunbiased in vivo active caspase-trapping assay [23]. The
caspase activity probe bVAD is the best way to deter-
mine whether caspases are active since bVAD binds irre-
versibly to all caspases that are active. In other words, if
a caspase is active and its active site is available, bVAD
will bind to it. Because bVAD is biotinylated, it can be
isolated on streptavidin agarose along with any active
caspase that is bound to it. This strategy has also the ad-
vantage of enriching for the apical active caspase rather
than the downstream caspases in a pathway that involves
a cascade of caspase activation. To determine which cas-
pases are active, FDDKI and WT mice were injected in
one hippocampus with 100 nmol of bVAD. In these
experiments, we utilized 6 (Figure 3A) or 5 (Figure 3B)
month-old mice since the memory deficits of FDDKI
mice start at around 4–5 months of age [3]. Two hrs
post treatment, the injected region and the contra-
lateral non-injected area were dissected, and bVAD-
caspase complexes were isolated on streptavidin-agarose
beads and analyzed by Western blotting. bVAD captured
greatly more FL-caspase-9, but not FL-caspase-8, from
the hippocampus of the FDDKI sample as compared to
the WT littermate sample (Figure 3A). The binding was
specific because streptavidin-agarose beads did not
pull-down active FL-caspase-9 from homogenates pre-
pared from the contra-lateral, non-injected sample. Cl.-
caspase-3 and −6 were not trapped by bVAD
(Figure 3A). The inability to isolate cl.-caspase-3 and
cl.-caspase-6 may depend on the fact that bVAD inhibits
caspase-9 activity, thereby inhibiting processing of ef-
fector caspases-3 and −6 by active caspase-9. This possi-
bility is not very likely because in FDDKI mice there is
probably ongoing caspase activation and bVAD will bind
to any active caspase present at the moment of bVAD ad-
ministration. Alternatively, cl.-caspase-3 may not be
available for bVAD-binding because it is complexed
in vivo with endogenous inhibitor of apoptosis proteins
(IAPs). Lastly, cl.-caspase-3 and cl.-caspase-6 may be
captured by bVAD at very low levels that are below the
detection power of our experimental system. This is in-
deed a possibility given the low level of material that can
be harvested in this experimental setting and the evi-
dence that cl-caspase-3 and cl-caspase-6 are not detect-
able in the input material either.
To determine whether active caspase-9 was present in
synaptic fractions, we repeated the experiment and per-
formed bVAD pull-downs from synaptosomal fractions.
As shown in Figure 3B, active caspase-9 was also iso-
lated from synaptosomal fractions of FDDKI but not WT
mice. Blotting for caspase-3, -6 and −8 showed once
more absence of detectable active caspase-3, -6 or −8 in
these synaptosomal preparations (data not shown). To
formally exclude that the differences between WT and
FDDKI mice illustrated above did not depend on
Figure 2 The caspase inhibitor LEHD-fmk rescues the memory deficit of FDDKI mice. Sequential NOR experiments on FDDKI and WT mice.
The first NOR was without treatment (no treat. 1); the second was performed after injecting in the lateral ventricle 1 μl of PBS-8%DMSO/800 μM
Z-LEHD-fmk (Z-LEHD-fmk); the third NOR was without treatment (no treat. 2); the fourth was performed after injecting 1 μl of PBS-8%DMSO/
800 μM Z-DEVD-fmk (Z-DEVD-fmk). The resting-days between each NOR are indicated in the X axis (1d., 2d. and 1d.). Training trials are reported in
A as: Time-Spent-Exploring (left panel), discriminatory ratio (right panel), which is calculated as time-spent-exploring Object 1/time-spent-
exploring Object 1+ time-spent-exploring Object 2. Data relative to the test trials are reported in B. The discriminatory ratio is calculated as time-
spent-exploring the Novel Object/time-spent-exploring the Novel Object + time-spent-exploring Object 2. WT mice spent more time exploring
the novel object showing normal object recognition, while FDDKI mice present amnesia and do not distinguish the new object from the old one
(B, no treat. 1). Notably, Z-LEHD-fmk rescues the deficit of FDDKI mice while does not affect the NOR of WT mice (Z-LEHD-FMK in B). FDDKI mice
relapsed into amnesia (no treat. 2 in B), indicating that the therapeutic effect of Z-LEHD-fmk is short-lived. DEVD-fmk neither rescues the amnesia
of FDDKI mice nor it affects the NOR ability of WT mice (Z-DEVD-FMK in B). Objects were changed after each experiment. A paired two-sample t-
test was used to test for significance between the discriminatory ratios between the groups.
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Figure 3 High levels of active initiator caspase-9 in FDDKI mice. A, Homogenates (input) were prepared from the bVAD injected (+bVAD)
and contralateral non-injected (con.) hippocampal regions of WT and FDDKI mice. Active caspases were isolated from homogenates with
streptavidin-agarose-beads pull-down. Western blot analysis shows that the caspase inhibitor bVAD traps FL-caspase-9 only from the bVAD
injected FDDKI mouse hippocampus; FL-caspase-8, cl.caspase-3 and cl.-caspase-6 are not trapped. B, In a similar experiment, the streptavidin-
agarose-beads pull-down experiment was performed from the P2 fractions. The P2 fractions represent crude synaptosomal fractions (see Material
and Methods for details about these preparations). Again, active FL-caspase-9 is isolated from FDDKI but not WT mice. C, Organotypic
hippocampal cultures from either FDDKI or WT mice were incubated for 3 hrs with 45 μM bVAD. After lysis, active caspases were isolated from
homogenates. Again, caspase-9 was the only active caspase isolated. Albeit traces of active caspase-9 are found in the WT samples, the levels
found in the FDDKI hippocampus are greatly elevated. The blots shown in A, B and C are representative of duplicate experiments.
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typic hippocampal cultures from 5 month-old WT and
FDDKI mice. BVAD trapped significantly more active
caspase-9 from organotypic hippocampal culture of
FDDKI mice than WT littermates (Figure 3C). Once
again, we could not detect active FL-caspase-8, cl.-cas-
pase-3 and cl.-caspase-6 neither in WT nor in FDDKI
sample. Altogether these data indicate that caspase-9 is
excessively activated in Danish dementia mice. More-
over, the data suggest that, if the Danish mutation trig-
gers a cascade of caspase activation, caspase-9 is the
apical caspase in such a cascade.
Specific inhibition of caspase-9 with Pen1-XBIR3 provides
therapeutic rescue of the object recognition deficit
The findings that reducing caspase activity with com-
mercial peptide inhibitors rescues synaptic/memory defi-
cits and that caspase-9 is active in FDDKI mice, suggest
that caspase-9 is involved in the pathogenesis of thesedeficits. To specifically determine the functional rele-
vance of caspase-9 activity in memory loss pathogenesis,
we specifically inhibited caspase-9. As a control, we also
used a specific inhibitor of caspase-8 activity. Mammals
express a family of cell death inhibiting proteins known
as IAPs. IAPs contain BIR domains (Baculovirus Inhibi-
tor of apoptosis protein Repeats), which perform specific
functions. One member of this family, XIAP, is a potent
specific inhibitor of active caspase-9, caspase-3, and cas-
pase-7. The XIAP-BIR3 domain is a specific inhibitor of
active caspase-9, and the XIAP-BIR2-linker domain inhi-
bits active caspase-3 and caspase-7 [24]. Serpins are also
caspases inhibitors and CrmA (a cowpox serpin) inhibits
caspase-8 (as well as caspase-1, which is involved in in-
flammatory responses) but not other murine caspases
[25]. To provide intracellular delivery, XIAP-BIR3 and
CrmA were disulfide-linked to Penetratin1 (Pen1), a
cell-penetrating peptide [23]. Upon entry into the cell
the reducing environment of the cytoplasm reduces the
Figure 4 (See legend on next page.)
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Figure 4 Inhibition of caspase-9 with Pen1-XBIR3 rescues the memory deficits of FDDKI mice. Twenty-five days after a cannula was
implanted in the lateral ventricle, mice were injected in the lateral ventricle either with 2 μl of PBS/23 μM Pen1-XBIR3, 2 μl of PBS/16 μM Pen1-
CrmA, or 2 μl of PBS alone (WT/PBS N = 7, WT/Pen1-XBIR3 N = 8, WT/Pen1-CrmA N = 7, FDDKI/PBS N = 8, FDDKI/Pen1-XBIR3 N = 8, FDDKI/Pen1-
CrmA N = 8). Injections were performed 1 h prior to the training section and 1 h before testing. WT and FDDKI mice spent the same amount of
time exploring the two identical objects on day 1 (A). WT mice spent more time exploring the novel object 24 h later, while FDDKI mice do not
recognize the new object (WT/Vehicle vs. FDDKI/Vehicle P = 0.0007) . Pen1-XBIR3 rescues this memory deficit (FDDKI/Pen1-XBIR3 vs. WT/Vehicle
P = 0.79; FDDKI/Pen1-XBIR3 vs. WT/Pen1-XBIR3 P = 0.89; FDDKI/Pen1-XBIR3 vs. WT/Pen1-CrmA P = 0.37; FDDKI/Pen1-XBIR3 vs. FDDKI /Vehicle P =
0.0013; FDDKI/Pen1-XBIR3 vs. FDDKI/Pen1-CrmA P = 0.0027), while Pen1-CrmA does not (FDDKI/Pen1-CrmA vs. WT/Vehicle P = 0.0079; FDDKI/Pen
1-CrmA vs. WT/Pen1-XBIR3 P = 0.0038; FDDKI/Pen1-CrmA vs. WT/Pen1-CrmA P = 0.034; FDDKI/Pen1-CrmA vs. FDDKI /Vehicle P = 0.24). (B). C and D,
The NOR test was repeated 5 days later without further treatments. The therapeutic effect of Pen1-XBIR3 is still significant (WT/Vehicle vs.
FDDKI/Vehicle P = 0.0003; FDDKI/Pen1-XBIR3 vs. WT/Vehicle P = 0.046; FDDKI/Pen1-XBIR3 vs. WT/Pen1-XBIR3 P = 0.44; FDDKI/Pen1-XBIR3 vs.
WT/Pen1-CrmA P = 0.95; FDDKI/Pen1-XBIR3 vs. FDDKI /Vehicle P = 0.03; FDDKI/Pen1-XBIR3 vs. FDDKI/Pen1-CrmA P = 0.028; FDDKI/Pen1-CrmA vs.
WT/Vehicle P = 0.0002; FDDKI/Pen1-CrmA vs. WT/Pen1-XBIR3 P = 0.0025; FDDKI/Pen1-CrmA vs. WT/Pen1-CrmA P = 0.0038; FDDKI/Pen1-crmA vs.
FDDKI/Vehicle P = 0.85). A paired two-sample t-test was used to test for significance between the discriminatory ratios between the groups.
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allows it to act at its target. We have previously shown
that Pen1-XBIR3 inhibits caspase-9 dependent cell death
using primary hippocampal neuron cultures, and that
Pen1-XBIR3 delivery to the CNS blocks caspase-9 in an
in vivo model of cerebral ischemia [23]. NOR experi-
ments were used to assess the effect of Pen1-XBIR3 on
memory. Six groups of mice (3 groups of FDDKI mice
and 3 groups of WT littermates) were injected in the lat-
eral ventricle either with vehicle alone, Pen1-XBIR3 or
Pen1-CrmA 1 hr before the training/testing trials. Pen1-
XBIR3 treated FDDKI mice spent significantly more time
exploring the novel object showing reversal of the mem-
ory deficits (Figure 4A and B). On the contrary, Pen1-
CrmA treated FDDKI mice showed memory deficits
comparable to those observed in vehicle-treated FDDKI
mice. Neither Pen1-XBIR3 nor Pen1-CrmA altered
memory in WT animals. Following 5 days of rest, a new
NOR test performed without treatments showed that
the therapeutic effect of Pen1-XBIR3 persisted for at
least 5 days post injection (Figure 4C and D). Our previ-
ous studies showed that one dose of Pen1-XBIR3 pro-
vided functional protection against ischemia for 3 weeks
post-infarction [23]. Thus, Pen1-XBIR3 rescued the
memory deficit of FDDKI mice, while Pen1-CrmA did
not. These data indicate that excessive activation of
caspase-9 in FDDKI mice is an essential step in the
pathogenesis of memory loss.
Discussion
We have tested whether caspases are involved in the
pathogenesis of synaptic plasticity deficits and memory
loss in FDDKI mice and have used an unbiased approach
to identify caspases that are critical for these patho-
logical processes. Our data show that caspase-9 is a me-
diator of synaptic plasticity and memory deficits in
FDDKI mice. We have used active caspase trapping with
bVAD, an irreversible pan-caspase inhibitor. This
method provides a reliable measurement of caspaseactivity through biochemical pull-down of active cas-
pases and has been shown to isolate active caspases-2,
-3, -7 -8, or −9 from cell lines [26], in primary neuron
cultures [27] and in vivo in the CNS [23]. With this
method we show that FDDKI mice have high levels of ac-
tive caspase-9 in hippocampal synaptosomes. This is the
first demonstration of a catalytically active initiator cas-
pase in the hippocampus of animal models of familial
dementia.
Inhibiting caspases with commercial peptide inhibitors
reversed synaptic plasticity deficits and memory loss in
FDDKI mice. The beneficial effect on memory was short-
lived and reversible. However, the commercial peptide
inhibitors are promiscuous [22] and can lead to misin-
terpretation of data. Thus, we treated mice with highly
specific inhibitors for caspase-8 (Pen1-CrmA) or
caspase-9 (Pen1-XBIR3). Only Pen1-XBIR3 reversed
memory deficits. The therapeutic effect remained signifi-
cant even 5 days after treatment. Therefore, we conclude
that active caspase-9 plays an essential role in the patho-
genesis of memory loss in FDDKI mice (Figure 5A and
B). Our previous findings showed that increased levels
of APP metabolites derived by β-secretase processing of
APP (sAPPβ and/or β-CTF) caused by loss of BRI2 pro-
tein in FDDKI mice are also responsible for synaptic/
memory deficits. The Danish mutation could alter APP
processing and prompt caspase-9 activation via inde-
pendent mechanisms, starting two pathogenic pathways
that are necessary but not sufficient to provoke the dis-
ease (Figure 5B). Alternatively, sAPPβ and/or β-CTF
may prompt caspase-9 activation, via a yet-to-be-defined
pathway, activation of caspase-9. In turn, active caspase-
9 mediates downstream events, which are still uncharac-
terized and may involve other caspases, leading to
synaptic and memory dysfunctions (Figure 5C).
Transgenic mice overexpressing human FAD mutant
APP (Tg2576 mice) display an Aβ-dependent enhanced
caspase-3 activation, and Z-DEVD-fmk restores cognitive
decline in Tg2576 mice [30]. It has also been shown that
Figure 5 Hypothetical model depicting the mechanisms by which caspase-9 can lead to alteration typical of neurodegenerative
disorders: memory loss, dystrophic neurites and neuronal loss. A and B, Previous work from our laboratory has shown that due to loss of
BRI2 protein (loss of function model), APP processing is increased during synaptic transmission and memory acquisition in FDD leading to
increased production of sAPPβ and β-CTF, leading to synaptic/memory deficits. We now show that caspase-9 is activated, via and unknown
mechanisms, in FDD. This increased caspase-9 activation leads to synaptic/memory deficits via a yet to be defined mechanism. In C, we postulate
a hypothetical pathway in which caspase-9 is activated by β-CTF and/or sAPPβ, perhaps via interaction with a membrane-bound receptor, sAPPβ-
R, such as DR6 [19]. Whether sAPPα and/or α-CTF can also trigger this pathway remains to be determined. In this context, it is worth noting that
BRI2 also inhibits α-secretase processing of APP [4,28,29]. Further studies will be needed to assess the role of the α-processing pathway of APP in
dementia. D and E, Aberrant activation of caspase-9 in synaptosomes causes functional impairments leading to synaptic plasticity and memory
acquisition deficits, with no noticeable anatomical changes. In F, we hypothesize that repetitive cycles of high caspase-9 activity can lead to
dystrophy of neurites. Prolonged and sustained activation of caspase-9 increases the probability that in any given neuron caspase-9 activity may
leak to the cell body and prompt the demise of the neuron.
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cits induced in vitro by synthetic Aβ [31]. The BIR2 do-
main of XIAP inhibits active caspase-3 and caspase-7 [24].
Altogether, these results have lead to the conclusion that
caspase-3, but not caspase-9, mediates the inhibition of
LTP by synthetic Aβ. This is in contrast with the observa-
tions that only caspase-9 is hyperactive in FDDKI mice
and that memory deficits of FDDKI mice are rescued by Z-
LEHD-fmk and XBIR3 but not Z-DEVD-fmk. Those
differences are consistent with the hypothesis that the def-
icits of FDDKI mice are Aβ-independent. Based on these
dissimilarities it could be argued that FDDKI and Tg2576
mice represent dementias caused by distinct pathogenic
mechanisms, involving either sAPPβ/β-CTF and caspase-
9 or Aβ and caspase-3, respectively. Alternatively, these
mice may reproduce distinct stages of a common pathway
leading to human dementia. It is also possible that either
FDDKI or Tg2576 mice develop synaptic/memory deficits
that are triggered by artificial harmful effects unrelated to
the pathogenesis of human dementias. In this regard, it is
important to emphasize that the mouse model that we
have analyzed, unlike transgenic mice, is genetically con-
gruous to the human disease, suggesting that the mechan-
isms underlying synaptic and memory impairments in
FDDKI mice faithfully reproduce the pathogenesis of
human dementia.
When aberrant caspase-9 activation is confined to syn-
aptic compartments, it leads to synaptic-memorydeficits, as it is the case for FDDKI mice (Figure 5D and
E). However, if activation of caspase-9 is recurring and
sustained, it may lead to dystrophy of neurites and to
the demise of any given neuron in which active caspase-
9 leaks into the neuronal cell body triggering effector
caspases and leading to genomic DNA fragmentation
(Figure 5F). Over time, these changes can result in neur-
onal loss and neuritic dystrophy that are typical features
of advanced neurodegenerative diseases.
Our study suggests that inhibiting caspase-9 activity
may be a viable therapeutic option in human dementias.
Here, we have used intraventricular administration of
Pen1-XBIR3 that provides direct delivery to the brain. In a
previous paper we have shown that direct parenchymal or
intranasal delivery of Pen1-XBIR3 is therapeutically effect-
ive in rat models of stroke [23]. From a therapeutic per-
spective, intranasal delivery is a very attractive treatment
strategy for CNS disorders because it provides direct, non-
invasive access to the brain via the olfactory pathway.
Intranasal delivery combined with the cell-permeant pep-
tide Pen1 makes Pen1-XBIR3 an attractive therapeutic
compound for treatment of human dementias.
Ethical statement regarding the use and well fare of mice
Mice were handled according to the Ethical Guidelines
for Treatment of Laboratory Animals of Albert Einstein
College of Medicine. The procedures were described and
approved in animal protocol number 20100404.
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Mice
FDDKI, mice are on a C57BL/6 J background and were
generated and maintained at the Animal facility of the
Albert Einstein College of Medicine. Mice were handled
according to the Ethical Guidelines for Treatment of La-
boratory Animals of Albert Einstein College of Medicine.
The procedures were described and approved in animal
protocol number 200404.
Electrophysiology
Transverse hippocampal slices (400 μm) from 13–
14 month old WT and FDDKI mice were transferred to a
recording chamber where they were maintained at 29°C
and perfused with artificial cerebrospinal fluid (ACSF)
continuously bubbled with 95% O2 and 5% CO2. The
ACSF composition in mM was: 124 NaCl, 4.4 KCl, 1
Na2HPO4, 25 NaHCO3, 2 CaCl2, 2 MgSO4, and 10 glucose.
CA1 field-excitatory-post-synaptic potentials (fEPSPs) were
recorded by placing both the stimulating and the recording
electrodes in CA1 stratum radiatum. After 90 minutes in-
cubation, 10 μM Z-VAD-fmk was added. For LTP experi-
ments, a 30 min baseline was recorded every minute at an
intensity that evoked a response approximately 35% of the
maximum evoked response. LTP was induced using a θ-
burst stimulation (four pulses at 100 Hz, with bursts
repeated at 5 Hz and each tetanus including one ten-burst
train). Responses were recorded for 90 min after tetaniza-
tion and plotted as percentage of baseline fEPSP slope. Z-
VAD-fmk is from R&D Systems.
Brain cannulation and injections
Dr. Xiaosong Li at the Animal Physiology core of the
Albert Einstein College of Medicine surgically implanted
the cannula. Using stereotaxic surgery performed under
ketamine/xylazine anesthesia, mice were implanted with
cannula (Plastics One Inc.) into the lateral ventricle
(coordinates from bregma: A/P −0.4 mm, M/L − 1 mm,
D/V −2.5 mm) or hippocampus (coordinates from
bregma: A/P −2.45 mm, M/L − 1.5 mm, D/V −1.7 mm).
Z-LEHD-fmk (800 nM), Z-DEVD-fmk (800 nM), or sa-
line were delivered into the lateral ventricle at the rate
of 1 μl per minute using a CMA 400 syringe pump, for a
total volume of 1 μl. Pen1-XBIR3 (23 μM), Pen1-CrmA
(16 μM), or saline were delivered into the lateral ven-
tricle at a rate of 1 μl per minute using a CMA 400 syr-
inge pump, for a total volume of 2 μl. Z-LEHD-fmk and
Z-DEVD-fmk are from R&D Systems.
In vivo caspase activity assay
Biotin-Val-Ala-Asp(OMe)-fluoromethylketone (bVAD; MP
Biomedicals) was used as an in vivo molecular trap for ac-
tive caspases. 5 μl of bVAD (100 nmol) was injected into
one hippocampus along with a blue dye using a CMA 400syringe pump at a rate of 1 μl per minute. Mice were sacri-
ficed 2 hrs later, and the region with the blue dye was iso-
lated from the rest of the hippocampus. The same region
was collected on the contralateral hippocampus as the un-
treated/control. These regions were lysed separately in
10% glycerol, 150nM NaCl, 0.2% NP-40, 20 mM Tris–HCl
(pH 7.3) with protease and phosphatase inhibitors. For
bVAD-caspase complex precipitation, protein lysates were
precleared by rocking with Sepharose beads (GE Health-
care) for 1 h at 4°C. Precleared lysate was centrifuged, and
the supernatant was transferred to 30 μl of streptavidin-
agarose beads (Sigma) and rocked gently overnight at 4°C.
Beads were washed/centrifuged (300 μl washes, 5000 rpm
for 1 min) 15 times with bVAD lysis buffer. After the final
wash/pelleting, caspase-bVAD complexes were boiled off
of streptavidin beads into 1× SDS sample buffer without
reducing agent. Beads were pelleted at 14,000 rpm for
10 min, and the supernatant was transferred to a fresh tube
and resolved by SDS-PAGE.
Organotypic hippocampal slices caspase activity assay
Organotypic hippocampal slices were prepared and cul-
tured as described previously [32]. Briefly, 400 μm
slices were prepared using a tissue chopper. Slices were
transferred onto a cell culture insert that was placed
into a 6-well plate in an incubator with 5% CO2 and
78% O2. The plate contained 1 ml of culture media
(MEM with Glutamax-1 supplemented with D-glucose,
horse serum, nystatin, HEPES, EBSS, and Pen-Strep).
The slices were cultured in the interface method. After
24 h of culture, the media was replaced with culture
media containing 45 μM bVAD for 3 h after which the
slices were collected and lysed separately in 10% gly-
cerol, 150nM NaCl, 0.2% NP-40, 20 mM Tris–HCl (pH
7.3) with protease and phosphatase inhibitors. bVAD-
caspase complex precipitation was performed by pre-
clearing with Sepharose beads and isolation with
streptavidin-agarose beads as described in the preced-
ing chapter. After the final wash/pelleting, caspase-
bVAD complexes were boiled off of streptavidin beads
into 1× SDS sample buffer without reducing agent.
Beads were pelleted at 14,000 rpm for 10 min, and the
supernatant was transferred to a fresh tube and
resolved by SDS-PAGE.
Open field and novel object recognition
The mice were acclimated to the testing room for
30 min after being moved. Each mouse was placed into
a 40 cm × 40 cm open field chamber with opaque walls,
2 ft high. Each mouse was allowed to habituate to the
normal open field box for 10 min, and repeated again
24 h later, in which we manually recorded the number
of entries into and time spent in the center of the loco-
motor arena. As previously reported [3], open field
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bituation, sedation, risk assessment and anxiety-like be-
havior in novel environments.
Novel object recognition began 24 h after the second
open field session, and was performed as previously
described [3,33]. Briefly, NOR consisted of two sessions
24 h apart. In the first session, the mice were placed into
the open field chamber with two identical, non-toxic
objects, 12 cm from the back and sidewalls of the open
field box, and 16 cm apart from each other. An 8 min
session, in which the time exploring each object was
recorded; an area 2 cm2 surrounding the object is
defined such that nose entries within 2 cm of the object
were recorded as time exploring the object. We will refer
to this as training trial. The animal was then returned to
its home cage and 24 h late, placed into the open field
box again. This time, there was one object identical to
the previous one, and one novel object. We will refer to
this as the test trial. The mice were given another 6 min
to explore, and the amount of time exploring each object
was recorded. Mice that spent < 7 seconds exploring the
objects were omitted from the analysis [33]. Results were
recorded as Time Spent Exploring each object an object
discrimination ratio (ODR), which is calculated by divid-
ing the time the mice spent exploring object 1 (for the
training trial) or the novel object (for the test trial) by
the total amount of time exploring the two objects.
Synaptosome preparation and Western blot analysis
For synaptic preparations, isolated hippocampi were
homogenized (w/v = 10 mg tissue/100 ml buffer) in Hepes-
sucrose buffer (20 mM Hepes/NaOH pH 7.4, 1 mM
EDTA, 1 mM EGTA, 0.25 M sucrose) supplemented with
protease and phosphatase inhibitors. Homogenates were
centrifuged at 800 g for 10 min. The supernatant (S1) was
separated into supernatant (S2) and pellet (P2) by spinning
at 9,200 g for 15 min. Synaptosome fractions represent: S1,
post-nuclear-supernatant; S2, cytosol, soluble proteins and
light membrane; P2, crude synaptosomal fraction. The S1
and P2 fractions were analyzed by western blot using the
following antibodies: α-caspase-3 (9662/Cell signaling); α-
caspase-6 (9762/Cell Signaling); α-caspase-8 (4790/Cell
Signaling); α-caspase-9 (ab28131/Abcam. Secondary anti-
bodies conjugated with horse-radish peroxidase are from
Southern Biotechnology.
Image scanning and analysis
Western blot images were scanned with Epson Perfec-
tion 3200 Photo scanner and were analyzed with NIH
ImageJ software.
Statistical analysis
All data are shown as mean ± s.e.m. Statistical tests
included two-way ANOVA for repeated measures and t-test when appropriate. All experiments were performed
in a blinded fashion.
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